Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma

October 15, 2020 Auto Bot Bayer, Clinical Trials, patients, reports, results, Rituximab 0

Shots:

  • The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing treatment
  • The P-II study met its 1EP of prolonged PFS, safety is consistent with previously published data on the individual components of the combination, no new safety signals were identified
  • Aliqopa is a PI3K inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells and is an approved treatment for patients with relapsed FL prior treated with two systemic therapies

    Click here to­ read the full press release/ article | Ref: Businesswire Image: Business Insider

The post Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma first appeared on PharmaShots.